Chelsey Chen

Chelsey Chen

Auto-generated profile, based on publicly available information

Chelsey Chen

Institute for Cell Engineering, and Armstrong Oxygen Biology Research Center, Johns Hopkins University School of Medicine 1 Department of Genetic Medicine Baltimore, MD

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2021 in Science Advances
Verified
Journal Article
Open access
YWYufeng Wang
Yufeng Wang
YLYajing Lyu
Yajing Lyu
KTKangsheng Tu
Kangsheng Tu
QXQiuran Xu
Qiuran Xu
YYYongkang Yang
Yongkang Yang
GSGregg L. Semenza
Gregg L. Semenza
Histone citrullination by PADI4 is required for hypoxia-induced gene expression.

5 May 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RWRu Wang
Ru Wang
Ines GodetInes Godet
Ines Godet
YYYongkang Yang
Yongkang Yang
SSShaima Salman
Shaima Salman
HLHaiquan Lu
Haiquan Lu
GSGregg L. Semenza
Gregg L. Semenza
Significance: Hypoxia (reduced oxygen availability) is a common finding in the tumor microenvironment and plays a critical role in stimulating the metastasis of breast cancer cells from the primary tumor to distant organs, which is closely related to patient mortality. Critical transcriptional responses to reduced O2availability are mediated by hypoxia-inducible factors (HIFs). In this study, we demonstrate that hypoxia induces HIF-dependent expression of a disintegrin and metalloproteinase 12 (ADAM12), which clips off the extracellular domain of the membrane-bound heparin-binding epidermal growth factor-like growth factor (HB-EGF). The liberated extracellular domain of HB-EGF binds to the epidermal growth factor receptor, triggering a signal transduction pathway that endows breast cancer cells with increased capability for cell migration and invasion, leading to distant metastasis.

9 December 2022 in Science Advances
Verified
Journal Article
Open access
YYYongkang Yang
Yongkang Yang
CCChelsey Chen
Chelsey Chen
QZQiaozhu Zuo
Qiaozhu Zuo
Haiquan LuHaiquan Lu
Haiquan Lu
SSShaima Salman
Shaima Salman
GSGregg L. Semenza
Gregg L. Semenza
Hypoxia is a key characteristic of the breast cancer microenvironment that promotes expression of the transcriptional activator hypoxia-inducible factor 1 (HIF-1) and is associated with poor patient outcome. HIF-1 increases the expression or activity of stem cell pluripotency factors, which control breast cancer stem cell (BCSC) specification and are required for cancer metastasis. Here, we identify nuclear prelamin A recognition factor ( NARF ) as a hypoxia-inducible, HIF-1 target gene in human breast cancer cells. NARF functions as an essential coactivator by recruiting the histone demethylase KDM6A to OCT4 bound to genes encoding the pluripotency factors NANOG, KLF4, and SOX2, leading to demethylation of histone H3 trimethylated at lysine-27 (H3K27me3), thereby increasing the expression of NANOG, KLF4, and SOX2, which, together with OCT4, mediate BCSC specification. Knockdown of NARF significantly decreased the BCSC population in vitro and markedly impaired tumor initiation capacity and lung metastasis in orthotopic mouse models.

24 June 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SKShunsuke Kimura
Shunsuke Kimura
CPChun Shik Park
Chun Shik Park
LMLindsey E. Montefiori
Lindsey E. Montefiori
Ilaria IacobucciIlaria Iacobucci
Ilaria Iacobucci
PPPetri Pölönen
Petri Pölönen
CMCharles G Mullighan
Charles G Mullighan
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.

24 April 2025 in Cancer Discovery
Verified
Journal Article
Open access
BKBenjamin M. Kahn
Benjamin M. Kahn
RNRaymond W.S. Ng
Raymond W.S. Ng
IKIl-Kyu Kim
Il-Kyu Kim
CECody Eskandarian
Cody Eskandarian
CCChelsey O. Chen
Chelsey O. Chen
BSBen Z. Stanger
Ben Z. Stanger
Lymph nodes (LN) are the staging grounds for antitumor immunity; therefore, their high susceptibility to metastatic colonization is a paradox. Previous studies have suggested that extrinsic tumor-derived factors precondition the draining LN to enable tumor cell survival by promoting a state of immune suppression. In this study, we investigate whether properties of the LN itself may impede its ability to clear metastasizing tumor cells. Using multiple immunocompetent transplant models, we show that LNs possess intrinsic features, independent of preconditioning, which make them an advantageous site for tumor cells to evade T-cell control. Tumor growth in the LN is facilitated by regulatory T cells, which locally suppress the cytolytic capacity of tumor-specific CD8+ T cells by restricting IL2. These findings identify an intrinsic mechanism that contributes to the high rate of LN metastasis in solid tumors. Significance: As an immune organ, the LN’s paradoxical susceptibility to metastasis has been attributed to immunosuppressive conditioning by tumor-secreted factors. We identify regulatory T cell restriction of IL2 from CD8+ T cells as an intrinsic property of LNs that renders them susceptible to metastatic colonization. See related commentary Menzel and Padera, p.1780

2 April 2026 in Journal of Experimental Medicine
Verified
Journal Article
Open access
SSShaima Salman
Shaima Salman
THTina Y. Huang
Tina Y. Huang
YHYousang Hwang
Yousang Hwang
AKAnmol Kumar
Anmol Kumar
EDEmmanuel Datan
Emmanuel Datan
GSGregg L. Semenza
Gregg L. Semenza
Hypoxia-inducible factors 1 and 2 (HIF-1/2) function as master regulators of cancer progression by regulating angiogenesis, cancer stem cell specification, epithelial–mesenchymal transition, immune evasion, tissue invasion, and metastasis. We utilized computer-aided drug discovery and cell-based reporter assays to identify dual HIF-1/2 inhibitors, which bind directly to highly conserved domains of HIF-1α and HIF-2α, disrupt dimerization with HIF-1β, and trigger proteasomal degradation, thereby inhibiting HIF-1/2 transcriptional activity. These inhibitors and derivative compounds block growth and vascularization of breast, colorectal, head/neck, melanoma, and prostate tumors as monotherapy, and overcome resistance to anti-CTLA-4 or anti-PD-1 immunotherapy, with an aggregate complete response rate of over 50%, through reprogramming of the tumor immune cell microenvironment. Compared with the HIF-2–selective inhibitors belzutifan and PT2385, dual HIF-1/2 inhibitor 1.21S9N showed superior activity against breast and colorectal cancer models, respectively. PT2385 caused breathing abnormalities, whereas 1.21S9N did not. The drugs are orally bioavailable, and no safety concerns were identified even after extended or supratherapeutic dosing.